<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00033917</url>
  </required_header>
  <id_info>
    <org_study_id>R01NS027116</org_study_id>
    <nct_id>NCT00033917</nct_id>
  </id_info>
  <brief_title>Indomethacin Germinal Matrix Hemorrhage/Intraventricular Hemorrhage (GMH/IVH) Prevention Trial</brief_title>
  <official_title>Randomized Indomethacin Germinal Matrix Hemorrhage/Intraventricular Hemorrhage (GMH/IVH) Prevention Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <brief_summary>
    <textblock>
      The purpose of this multicenter trial is to determine if indomethacin prevents bleeding in
      the brain of very low birth weight preterm infants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intraventricular hemorrhage (IVH) or bleeding in the brain remains a major problem of preterm
      infants. This randomized, placebo-controlled multicenter trial enrolled 505 infants of 600 to
      1250g birth weight to determine if indomethacin lowers the incidence of IVH, and 125 term
      infant controls. During this longitudinal trial, follow-up assessments have been performed at
      the ages of 3, 4 1/2, 6, 8, 12 and 16 years. The initial results at age 3 years revealed no
      advantages to the indomethacin group over and above the decreases in IVH, however, the
      results did show a significant increase in ventriculomegaly in the &quot;placebo&quot; group. Results
      at 4 1/2, 6 and 8 years of age showed beneficial effects of indomethacin on cognitive and
      behavioral outcomes over and above the effects on preventing IVH but not at later ages. At 12
      and 16 years, no significant influence of indomethacin on cognitive outcome was noted.

      Age, gender and zip-code matched control subjects were added when the preterm subjects were 8
      years. Throughout all subsequent testing, term controls have higher IQ and Peabody Picture
      Vocabulary Scores.

      Additional longitudinal volumetric, functional and diffusion tensor MR imaging studies showed
      differences between preterm and term control subjects at 8, 12 and 16 years of age. These
      were consistent with utilization of the right hemisphere and left cerebellum for language in
      the preterm group compared to term controls. No effects of indomethacin were seen.

      The study closed on 31 March 2012.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1989</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IVH at 5 Postnatal Days</measure>
    <time_frame>at 5 days</time_frame>
    <description>Cranial ultrasounds were performed daily for the first 5 postnatal days; the main outcome measure was intraaventricular hemorrhage (IVH) at 5 days of age</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Language Outcome</measure>
    <time_frame>at 8 years</time_frame>
    <description>Peabody Picture Vocabulary Test (PPVT) This is a semantic language test. The mean value is 100; standard deviation is 16 points. A higher score means better language; a lower score means poorer language.
There are no subscales to the PPVT. The measurement unit is points on a scale. A score &lt; 70 indicates severely abnormal language function.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">630</enrollment>
  <condition>Intraventricular Hemorrhage (IVH)</condition>
  <condition>Bleeding in the Brain</condition>
  <condition>Prematurity</condition>
  <condition>Very Low Birth Weight Infants</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>indomethacin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>indomethacin</intervention_name>
    <description>an anti-inflammatory drug</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>saline</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Preterm infants &lt; 1250 g birth weight

          -  Admitted to participating institution &lt; 6 hrs of age

          -  No evidence for congenital malformations

          -  Cranial US at 6 postnatal hours without evidence of Grades III - IV intraventricular
             hemorrhage
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Hours</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura R. Ment, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pediatrics, Yale University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brown University School of Medicine</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ment LR, Oh W, Ehrenkranz RA, Philip AG, Vohr B, Allan W, Duncan CC, Scott DT, Taylor KJ, Katz KH, et al. Low-dose indomethacin and prevention of intraventricular hemorrhage: a multicenter randomized trial. Pediatrics. 1994 Apr;93(4):543-50.</citation>
    <PMID>8134206</PMID>
  </reference>
  <reference>
    <citation>Ment LR, Oh W, Ehrenkranz RA, Phillip AG, Vohr B, Allan W, Makuch RW, Taylor KJ, Schneider KC, Katz KH, et al. Low-dose indomethacin therapy and extension of intraventricular hemorrhage: a multicenter randomized trial. J Pediatr. 1994 Jun;124(6):951-5.</citation>
    <PMID>8201485</PMID>
  </reference>
  <reference>
    <citation>Ment LR, Vohr B, Oh W, Scott DT, Allan WC, Westerveld M, Duncan CC, Ehrenkranz RA, Katz KH, Schneider KC, Makuch RW. Neurodevelopmental outcome at 36 months' corrected age of preterm infants in the Multicenter Indomethacin Intraventricular Hemorrhage Prevention Trial. Pediatrics. 1996 Oct;98(4 Pt 1):714-8.</citation>
    <PMID>8885951</PMID>
  </reference>
  <reference>
    <citation>Ment LR, Westerveld M, Makuch R, Vohr B, Allan WC. Cognitive outcome at 4 1/2 years of very low birth weight infants enrolled in the multicenter indomethacin intraventricular hemorrhage prevention trial. Pediatrics. 1998 Jul;102(1 Pt 1):159-60.</citation>
    <PMID>9714645</PMID>
  </reference>
  <reference>
    <citation>Ment LR, Vohr B, Allan W, Westerveld M, Sparrow SS, Schneider KC, Katz KH, Duncan CC, Makuch RW. Outcome of children in the indomethacin intraventricular hemorrhage prevention trial. Pediatrics. 2000 Mar;105(3 Pt 1):485-91.</citation>
    <PMID>10699097</PMID>
  </reference>
  <reference>
    <citation>Peterson BS, Vohr B, Staib LH, Cannistraci CJ, Dolberg A, Schneider KC, Katz KH, Westerveld M, Sparrow S, Anderson AW, Duncan CC, Makuch RW, Gore JC, Ment LR. Regional brain volume abnormalities and long-term cognitive outcome in preterm infants. JAMA. 2000 Oct 18;284(15):1939-47.</citation>
    <PMID>11035890</PMID>
  </reference>
  <reference>
    <citation>Ment LR, Vohr B, Allan W, Katz KH, Schneider KC, Westerveld M, Duncan CC, Makuch RW. Change in cognitive function over time in very low-birth-weight infants. JAMA. 2003 Feb 12;289(6):705-11.</citation>
    <PMID>12585948</PMID>
  </reference>
  <reference>
    <citation>Ment LR, Peterson BS, Meltzer JA, Vohr B, Allan W, Katz KH, Lacadie C, Schneider KC, Duncan CC, Makuch RW, Constable RT. A functional magnetic resonance imaging study of the long-term influences of early indomethacin exposure on language processing in the brains of prematurely born children. Pediatrics. 2006 Sep;118(3):961-70.</citation>
    <PMID>16950986</PMID>
  </reference>
  <reference>
    <citation>Ment LR, Kesler S, Vohr B, Katz KH, Baumgartner H, Schneider KC, Delancy S, Silbereis J, Duncan CC, Constable RT, Makuch RW, Reiss AL. Longitudinal brain volume changes in preterm and term control subjects during late childhood and adolescence. Pediatrics. 2009 Feb;123(2):503-11. doi: 10.1542/peds.2008-0025.</citation>
    <PMID>19171615</PMID>
  </reference>
  <reference>
    <citation>Gozzo Y, Vohr B, Lacadie C, Hampson M, Katz KH, Maller-Kesselman J, Schneider KC, Peterson BS, Rajeevan N, Makuch RW, Constable RT, Ment LR. Alterations in neural connectivity in preterm children at school age. Neuroimage. 2009 Nov 1;48(2):458-63. doi: 10.1016/j.neuroimage.2009.06.046. Epub 2009 Jun 25.</citation>
    <PMID>19560547</PMID>
  </reference>
  <reference>
    <citation>Luu TM, Vohr BR, Schneider KC, Katz KH, Tucker R, Allan WC, Ment LR. Trajectories of receptive language development from 3 to 12 years of age for very preterm children. Pediatrics. 2009 Jul;124(1):333-41. doi: 10.1542/peds.2008-2587.</citation>
    <PMID>19564317</PMID>
  </reference>
  <reference>
    <citation>Myers EH, Hampson M, Vohr B, Lacadie C, Frost SJ, Pugh KR, Katz KH, Schneider KC, Makuch RW, Constable RT, Ment LR. Functional connectivity to a right hemisphere language center in prematurely born adolescents. Neuroimage. 2010 Jul 15;51(4):1445-52. doi: 10.1016/j.neuroimage.2010.03.049. Epub 2010 Mar 25.</citation>
    <PMID>20347043</PMID>
  </reference>
  <reference>
    <citation>Mullen KM, Vohr BR, Katz KH, Schneider KC, Lacadie C, Hampson M, Makuch RW, Reiss AL, Constable RT, Ment LR. Preterm birth results in alterations in neural connectivity at age 16 years. Neuroimage. 2011 Feb 14;54(4):2563-70. doi: 10.1016/j.neuroimage.2010.11.019. Epub 2010 Nov 10.</citation>
    <PMID>21073965</PMID>
  </reference>
  <reference>
    <citation>Luu TM, Vohr BR, Allan W, Schneider KC, Ment LR. Evidence for catch-up in cognition and receptive vocabulary among adolescents born very preterm. Pediatrics. 2011 Aug;128(2):313-22. doi: 10.1542/peds.2010-2655. Epub 2011 Jul 18.</citation>
    <PMID>21768322</PMID>
  </reference>
  <reference>
    <citation>Constable RT, Vohr BR, Scheinost D, Benjamin JR, Fulbright RK, Lacadie C, Schneider KC, Katz KH, Zhang H, Papademetris X, Ment LR. A left cerebellar pathway mediates language in prematurely-born young adults. Neuroimage. 2013 Jan 1;64:371-8. doi: 10.1016/j.neuroimage.2012.09.008. Epub 2012 Sep 12.</citation>
    <PMID>22982585</PMID>
  </reference>
  <reference>
    <citation>Reiss AL, Kesler SR, Vohr B, Duncan CC, Katz KH, Pajot S, Schneider KC, Makuch RW, Ment LR. Sex differences in cerebral volumes of 8-year-olds born preterm. J Pediatr. 2004 Aug;145(2):242-9.</citation>
    <PMID>15289777</PMID>
  </reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2002</study_first_submitted>
  <study_first_submitted_qc>April 12, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2002</study_first_posted>
  <results_first_submitted>January 8, 2013</results_first_submitted>
  <results_first_submitted_qc>February 20, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 28, 2013</results_first_posted>
  <last_update_submitted>February 20, 2013</last_update_submitted>
  <last_update_submitted_qc>February 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Laura R. Ment</investigator_full_name>
    <investigator_title>Professor Pediatrics and Neurology</investigator_title>
  </responsible_party>
  <keyword>intraventricular hemorrhage (IVH)</keyword>
  <keyword>bleeding in the brain</keyword>
  <keyword>indomethacin</keyword>
  <keyword>prematurity</keyword>
  <keyword>very low birth weight infants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Birth Weight</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Indomethacin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Preterm neonates of 600 - 1250 g birth weight were enrolled between 6 and 12 postnatal hours at Yale New Haven Hospital (New Haven, CT), Maine Medical Center (Portland, ME) and Women and Infants' Hospital (Providence, RI).</recruitment_details>
      <pre_assignment_details>Cranial ultrasounds were performed on all study participants between 6 - 12 hours of age for group assignment. Subjects with major congenital cerebral malformations were excluded.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>IVH Negative Indomethacin</title>
          <description>Those subjects with no evidence for intraventricular hemorrhage (IVH) at 6 - 12 postnatal hours. These subjects were randomized to early low-dose indomethacin (0.1 mg/kg/d for 3 doses).</description>
        </group>
        <group group_id="P2">
          <title>IVH Negative Placebo</title>
          <description>These subjects also had no evidence for IVH at 6 - 12 hours. They were randomized to an equal volume of placebo.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="209"/>
                <participants group_id="P2" count="222"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="209"/>
                <participants group_id="P2" count="222"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Indomethacin</title>
          <description>subjects randomized to early low dose indomethacin</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Group randomized to an equal volume of placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="209"/>
            <count group_id="B2" value="222"/>
            <count group_id="B3" value="431"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age is expressed in postnatal hours</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.8" spread="2.3"/>
                    <measurement group_id="B2" value="7.9" spread="2.4"/>
                    <measurement group_id="B3" value="7.8" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="209"/>
                    <measurement group_id="B2" value="222"/>
                    <measurement group_id="B3" value="431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>IVH at 5 Postnatal Days</title>
        <description>Cranial ultrasounds were performed daily for the first 5 postnatal days; the main outcome measure was intraaventricular hemorrhage (IVH) at 5 days of age</description>
        <time_frame>at 5 days</time_frame>
        <population>All subjects had negative cranial ultrasounds with no evidence for IVH at 6 - 12 postnatal hours</population>
        <group_list>
          <group group_id="O1">
            <title>Indomethacin</title>
            <description>subjects randomized to early low dose indomethacin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group randomized to an equal volume of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>IVH at 5 Postnatal Days</title>
          <description>Cranial ultrasounds were performed daily for the first 5 postnatal days; the main outcome measure was intraaventricular hemorrhage (IVH) at 5 days of age</description>
          <population>All subjects had negative cranial ultrasounds with no evidence for IVH at 6 - 12 postnatal hours</population>
          <units>IVH</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Language Outcome</title>
        <description>Peabody Picture Vocabulary Test (PPVT) This is a semantic language test. The mean value is 100; standard deviation is 16 points. A higher score means better language; a lower score means poorer language.
There are no subscales to the PPVT. The measurement unit is points on a scale. A score &lt; 70 indicates severely abnormal language function.</description>
        <time_frame>at 8 years</time_frame>
        <population>Three hundred twenty eight subjects were available at age 8 years. They were tested with the PPVT.</population>
        <group_list>
          <group group_id="O1">
            <title>Indomethacin - no IVH</title>
            <description>Subjects randomized to indomethacin and had no IVH</description>
          </group>
          <group group_id="O2">
            <title>Indomethacin - IVH</title>
            <description>Randomized to indomethacin; had IVH</description>
          </group>
          <group group_id="O3">
            <title>Placebo - no IVH</title>
            <description>Randomized to placebo - no IVH</description>
          </group>
          <group group_id="O4">
            <title>Placebo - IVH</title>
            <description>Randomized to placebo; had IVH</description>
          </group>
        </group_list>
        <measure>
          <title>Language Outcome</title>
          <description>Peabody Picture Vocabulary Test (PPVT) This is a semantic language test. The mean value is 100; standard deviation is 16 points. A higher score means better language; a lower score means poorer language.
There are no subscales to the PPVT. The measurement unit is points on a scale. A score &lt; 70 indicates severely abnormal language function.</description>
          <population>Three hundred twenty eight subjects were available at age 8 years. They were tested with the PPVT.</population>
          <units>participants with PPVT score &lt; 70</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="135"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First 5 postnatal days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>IVH Negative Indomethacin</title>
          <description>Those subjects with no evidence for intraventricular hemorrhage (IVH) at 6 - 12 postnatal hours. These subjects were randomized to early low-dose indomethacin (0.1 mg/kg/d for 3 doses).</description>
        </group>
        <group group_id="E2">
          <title>IVH Negative Placebo</title>
          <description>These subjects also had no evidence for IVH at 6 - 12 hours. They were randomized to an equal volume of placebo.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>excessive bleeding</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="209"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>platelets &lt; 50,000</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>necrotizing enterocolitis</sub_title>
                <description>x-ray diagnosis</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>ischemic changes by ECHO</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="209"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>decreased urine output</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="209"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>creatinine &gt; 1.8 mg/dL</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="209"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Laura Ment</name_or_title>
      <organization>Yale University School of Medicine</organization>
      <phone>203-785-5708</phone>
      <email>laura.ment@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

